Applies to heparin: parenteral solution for injection.
Warning
Special Alerts:
A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].
Side effects include:
Hemorrhage, thrombocytopenia, HIT or HIT with thrombosis, injection site irritation, general hypersensitivity reactions, elevated aminotransferase concentrations.
For Healthcare Professionals
Applies to heparin: injectable kit, injectable solution, intravenous solution.
General
The most common adverse reaction was hemorrhage.[Ref]
Cardiovascular
Postmarketing reports: Hemorrhage, retroperitoneal hemorrhage[Ref]
Hematologic
Very common (10% or more): Thrombocytopenia (up to 30%)
Frequency not reported: Plasma lipoprotein lipase increased
Postmarketing reports: Heparin resistance[Ref]
Hypersensitivity
Frequency not reported: Conjunctivitis, cyanosis, tachypnea, feeling of oppression, angioneurotic edema, anaphylactic shock
Postmarketing reports: Chills, fever, urticaria, asthma, rhinitis, lacrimation, headache, nausea, vomiting, anaphylactoid reactions, shock, itching, burning[Ref]
Local
Frequency not reported: Erythematous nodules, infiltrated and sometimes eczema-like plaques
Postmarketing reports: Local irritation, erythema, mild pain, hematoma, ulceration, histamine-like reactions, skin necrosis[Ref]
Immunologic
Frequency not reported: Allergic reactions, hypereosinophilia
Postmarketing reports: Heparin-induced thrombocytopenia, heparin-induced thrombocytopenia and thrombosis, generalized hypersensitivity reactions[Ref]
Endocrine
Frequency not reported: Hypoaldosteronism
Postmarketing reports: Adrenal hemorrhage, acute adrenal insufficiency, fatal adrenal hemorrhage, aldosterone synthesis suppressed[Ref]
Metabolic
Frequency not reported: Plasma potassium increased, hyperkalemia, metabolic acidosis
Postmarketing reports: Rebound hyperlipidemia[Ref]
Musculoskeletal
Frequency not reported: Significant bone demineralization, spontaneous bone fracture
Postmarketing reports: Osteoporosis[Ref]
Dermatologic
Frequency not reported: Ecchymoses
Postmarketing reports: Cutaneous necrosis, delayed transient alopecia[Ref]
Hepatic
Frequency not reported: Serum transaminases increased
Postmarketing reports: ALT elevated significantly, AST elevated significantly[Ref]
Genitourinary
Postmarketing reports: Ovarian hemorrhage, priapism[Ref]
Renal
Frequency not reported: Renal function suppression[Ref]
